|
|
|
|
We conclude that minimal benefits accrued to the parkinsonian patients from long-term use of selegiline.No clinical evidence to support the claim of"neuroprotective"properties was found.Selegiline's major usefulness is to modify the fluctuating therapeutic response seen with L-dopa-carbidopa. |
|